InMed Pharmaceuticals CEO, Eric A. Adams, is interviewed by Science Journalist and Broadcaster Vivienne Parry Obe at the Edison Open House: Global Healthcare Conference 2021.
In this interview, Mr. Adams talks about rare cannabinoids and their therapeutic potential. Mr. Adams also speaks about the impact of a rare genetic skin disease called epidermolysis bullosa (EB) and InMed’s clinical trial of an investigational treatment for EB. He further discusses InMed’s glaucoma program and the potential of rare cannabinoid cannabinol, or ‘CBN’, the active pharmaceutical ingredient in its investigational treatments for EB and glaucoma.
